Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 4/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17094830 | 0.87 | PTPN1 (0.42) | GPR119POLBGRM5GRM1 | |
| SCHEMBL16465007 | 0.86 | NR1D1 (0.42) | NR1D1CYP2C19KMT2A | |
| SCHEMBL1769827 | 0.86 | NR1D1 (0.42) | NR1D1CYP2C19HRH1KMT2A | |
| SCHEMBL4598286 | 0.86 | POLB (0.43) | GPR119POLBGRM5GRM1 | |
| SCHEMBL14097932 | 0.86 | POLB (0.43) | GPR119POLBGRM5GRM1 | |
| SCHEMBL17094798 | 0.84 | POLB (0.42) | GPR119POLBGRM5GRM1 | |
| SCHEMBL17094785 | 0.83 | POLB (0.41) | GPR119POLBGRM5GRM1 | |
| SCHEMBL17094786 | 0.83 | CHIA (0.41) | GPR119POLB | |
| SCHEMBL16465009 | 0.83 | ACE (0.41) | HRH1 | |
| Lithium Ion SCHEMBL17094797 | 0.82 | POLB (0.40) | GPR119POLBGRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115038688-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-2906559-B1 | AZAINDOLINES | HOFFMANN LA ROCHE (CH) | 2017-02-08 | — | — | EP | disclosed |
| US-9309248-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150266879-A1 | AZAINDOLINES | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| US-7417144-B2 | e.g. 1-Methyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-4,5-dicarboxylic acid 5-[(4-chloro-phenyl)-amide]4-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; anticoagulant, antiinflammatory agent; thrombosis, peripheral arterial occlusive disease, stroke, arteriosclerosis, bypass grafting | HOFFMAN-LA ROCHE INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1907388-A1 | NOVEL HETEROARYL FUSED CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009883-A1 | NOVEL HETEROARYL FUSED CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015812-A1 | Factor Xa inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266879-A1 | AZAINDOLINES | AZI2, H1-5, CCNY | NR1D1 981/4885GPR119 1207/4885POLB 1206/4885 |
| US-20070015812-A1 | Factor Xa inhibitors | F12, F11, F2 | NR1D1 1754/4885GPR119 2863/4885POLB 3801/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | NR1D1 1453/4885GPR119 3517/4885POLB 2146/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | NR1D1 1453/4885GPR119 3517/4885POLB 2146/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | NR1D1 1453/4885GPR119 3517/4885POLB 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.